{"organizations": [], "uuid": "1d78d340f26b95bcf66c1553dab4cddce8888803", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180221.html", "section_title": "Archive News &amp; Video for Wednesday, 21 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sartorius-stedim-biotech-2017-unde/brief-sartorius-stedim-biotech-2017-underlying-ebitda-up-by-2-2-idUSFWN1QA153", "country": "US", "domain_rank": 408, "title": "BRIEF-Sartorius Stedim Biotech 2017 Underlying EBITDA Up By 2.2%", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.942, "site_type": "news", "published": "2018-02-21T14:21:00.000+02:00", "replies_count": 0, "uuid": "1d78d340f26b95bcf66c1553dab4cddce8888803"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sartorius-stedim-biotech-2017-unde/brief-sartorius-stedim-biotech-2017-underlying-ebitda-up-by-2-2-idUSFWN1QA153", "ord_in_thread": 0, "title": "BRIEF-Sartorius Stedim Biotech 2017 Underlying EBITDA Up By 2.2%", "locations": [], "entities": {"persons": [{"name": "sartorius", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 21 (Reuters) - SARTORIUS STEDIM BIOTECH SA:\n* SARTORIUS STEDIM BIOTECH TARGETS CONTINUED PROFITABLE GROWTH - SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025\n* SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025\n* NEW MEDIUM-TERM TARGETS: UNDERLYING EBITDA MARGIN OF ABOUT 30 PERCENT IN 2025\n* 2017 UNDERLYING EBITDA INCREASED BY 2.2% TO €294.9 MILLION‍​\n* 2017 INCREASE IN SALES REVENUE BY AROUND 4.1% TO EUR 1,081.0 MILLION\n* FORECASTS A RISE IN SALES REVENUE BY ABOUT 7% TO 10% IN 2018\n* SEES 2018 INCREASE OF UNDERLYING EBITDA MARGIN BY APPROX. 0.5 PERCENTAGE POINTS OVER PRIOR-YEAR FIGURE.\n* OUTLOOK 2018 CAPEX IS EXPECTED TO BE AT APPROX. 15% OF SALES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-21T14:21:00.000+02:00", "crawled": "2018-02-22T17:44:47.000+02:00", "highlightTitle": ""}